## Diagnosis and Clinical Context **Key Point:** This patient presents with classic pelvic inflammatory disease (PID) — lower abdominal pain, fever, purulent discharge, cervical motion tenderness, and adnexal tenderness following recent unprotected intercourse. **High-Yield:** The gram-negative diplococci on Gram stain strongly suggest *Neisseria gonorrhoeae*, one of the two most common causative organisms of PID (the other being *Chlamydia trachomatis*). ## Antibiotic Regimen for PID ### CDC/WHO Recommended First-Line Therapy | Component | Agent | Dosing | Rationale | |-----------|-------|--------|----------| | Cephalosporin | Ceftriaxone | 250 mg IM single dose | Covers *N. gonorrhoeae* (including resistant strains) | | Tetracycline | Doxycycline | 100 mg PO BD × 14 days | Covers *C. trachomatis* and anaerobes | **Clinical Pearl:** The combination of ceftriaxone + doxycycline covers both major pathogens and provides broad anaerobic coverage. This is the gold standard outpatient regimen for PID [cite:Park 26e Ch 23]. ### Why This Regimen? 1. **Gram-negative diplococci** = *N. gonorrhoeae* → requires cephalosporin (fluoroquinolones no longer recommended due to resistance). 2. **Dual coverage** = *Chlamydia* is co-infected in 30–40% of gonococcal PID; doxycycline is essential. 3. **14-day duration** = Standard for PID to prevent sequelae (tubo-ovarian abscess, infertility, ectopic pregnancy). **Mnemonic:** **CTG** — *Ceftriaxone + Tetracycline (doxycycline) + Gonorrhea/Chlamydia coverage*. ## Alternative Regimens For hospitalized or severe PID: - **IV:** Cefoxitin 2 g IV Q6H or ceftriaxone 1 g IV Q12H + doxycycline 100 mg PO/IV BD - **Add clindamycin** if tubo-ovarian abscess or severe sepsis suspected. **Warning:** Fluoroquinolones (ciprofloxacin) are NO LONGER recommended for gonorrhea due to widespread resistance; amoxicillin is inadequate for *N. gonorrhoeae*; metronidazole alone does not cover gonorrhea or chlamydia. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.